BioStock interview

Date: 2023-12-05

Last week, Alzinova AB shared positive topline results from the phase 1b study with our vaccine candidate ALZ-101 against Alzheimer's disease. The full analysis of study data for ALZ-101 is expected to be completed in Q1 2024, and BioStock - Connecting Innovation and Capital has taken the time to talk to our CEO, Kristina Torfgård, to get an insight into our major steps forward.

Read the interview below!

BioStock interview (in Swedish)